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Abstract
Objective: To identify baseline demographic and clinical risk factors associated with poor CD4 and weight response after
initiation of antiretroviral therapy (ART) in a cohort of human immunodeficiency virus (HIV)-infected children in KwaZulu-
Natal, South Africa.
Methods: We performed a retrospective cohort study of 674 children initiating antiretroviral therapy at McCord and St.
Mary’s hospitals in KwaZulu-Natal, South Africa, from August 2003 to December 2008. We extracted data from paper
charts and electronic medical records to assess risk factors associated with CD4 and weight response using logistic
regression.
Results: From the initial cohort of 901 children ,10 years old initiating ART between August 2003 and December 2008, we
analyzed 674 children with complete baseline data. Viral suppression rates (,400 copies/ml) were 84% after six months of
therapy and 88% after 12 months of therapy. Seventy-three percent of children achieved CD4 recovery after six months and
89% after 12 months. Weight-for-age Z-score (WAZ) improvements were seen in 58% of children after six months of ART
and 64% after 12 months. After six months of ART, lower baseline hemoglobin (p=0.037), presence of chronic diarrhea
(p=0.007), and virologic failure (p=0.046) were all associated with poor CD4 recovery by multivariate logistic regression.
After 12 months of ART, poor CD4 recovery was associated with higher baseline CD4% (p=0.005), chronic diarrhea
(p=0.02), and virologic failure (p,0.001). Age less than 3 years at ART initiation (p=0.0003), higher baseline CD4%
(p,0.001), and higher baseline WAZ (p,0.001) were all associated with poor WAZ improvements after 6 months by
multivariate logistic regression.
Conclusion: The presence of chronic diarrhea at baseline, independent of nutritional status and viral response, predicts poor
CD4 recovery. Age at initiation of ART is an important factor in early WAZ response to ART, while viral suppression strongly
predicts CD4 recovery but not WAZ improvement.
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Introduction
Antiretroviral therapy (ART) has been shown to dramatically
improve clinical outcomes, immune status, and growth parameters
among children infected with HIV [1,2,3,4,5,6,7,8]. Children’s
immune and weight response to ART differs based on age at ART
initiation and degree of viral suppression [3,9,10,11]. As shown in
recent adult studies [12], there are likely other baseline factors
contributing to differential immunologic responses. Baseline clinical
and demographic factors have been used to predict mortality in
HIV-infected children on ART [13,14,15,16,17]. However, few
baseline clinical characteristics other than age, CD4% and viral
response have been examined as potential predictors of weight and
immune response in HIV-infected children.
Published cohort studies have generated conflicting results
regarding baseline CD4% and age as predictors of CD4 recovery
[3,10,11,18]. Some studies found improved early CD4 response in
younger children [3,10,11], while others found no difference [18].
A similar discrepancy exists for baseline CD4% as a predictor of
CD4 response [10]. These studies, however, did not assess other
potential clinical predictors of early immunologic and weight
response such as the presence of chronic diarrhea, tuberculosis,
opportunistic infections or anemia. Clinicians could potentially use
these factors to identify children at higher risk of poor immune
response to ART and target them for more intense monitoring and
closer follow-up.
We performed a retrospective analysis of baseline clinical and
demographic risk factors as predictors of CD4 recovery and weight
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from two medical centers in South Africa. Our goal was to identify
clinically significant risk factors for poor weight gain and CD4
recovery in children taking ART.
Materials and Methods
Ethics Statement
The protocol was approved by McCord Hospital’s Research
Ethics Committee, St. Mary’s Hospital’s Ethics Committee and
the Partners Human Research Committee. All patients (or their
adult guardians/care givers) accessing care at McCord Hospital
signed a written consent authorizing storage of their medical
information on an electronic medical record database used for
clinical and research purposes. We did not obtain individual
consent.
Study Design
We performed a retrospective cohort study using paper charts
and electronic medical records from HIV-infected pediatric
patients (,10 years old) who initiated ART at McCord Hospital’s
Sinikithemba Clinic and St. Mary’s Hospital in KwaZulu-Natal,
South Africa, from August 2003 to December 2008. We analyzed
clinical and demographic characteristics at the time of ART
initiation, as well as, viral suppression at six and 12 months
post-ART initiation as potential predictors of CD4 and WAZ
response.
Study Population and Standard of Care
McCord Hospital is a semi-private, urban hospital providing
care for a mostly Zulu-speaking population in Durban, South
Africa. St. Mary’s Hospital is a semi-private, rural hospital for a
mostly Zulu-speaking population in Marrianhill, South Africa. A
total of 901 children ,10 years old initiated ART at McCord
Hospital’s Sinikithemba Clinic and St. Mary’s Hospital during the
study period. We followed patients from the time they initiated
ART until they died, transferred care to another facility, were lost
to follow-up or until the study end date of May 31, 2009. During
the study period, children initiated ART when their HIV disease
reached World Health Organization (WHO) stage 3 or 4 and/or
their CD4 percentage fell to less than 20% in children younger
than 18 months of age, or less than 15% in children older than 18
months of age, in accordance with South African National
Treatment Guidelines [19]. Based on national guidelines in South
Africa, children less than 3 years of age received a Protease
Inhibitor (PI)-based first-line treatment regimen comprised of
lopinavir/ritonavir, stavudine and lamivudine [19]. Children older
than 3 years of age initiated a Non-Nucleotide Reverse Trans-
criptase Inhibitor (NNRTI)-based treatment regimen comprised of
efaverinez, stavudine and lamivudine [19]. According to local
guidelines, routine laboratory monitoring includes baseline CD4
and six monthly CD4 and viral loads [19].
Data Collection
We evaluated medical records from all patients who were #10
years old when they initiated ART at McCord Hospital’s
Sinikithemba Clinic (August 2003 to December 2008) and St.
Mary’s Hospital (January 2007 to December 2008). We accessed
electronic medical records at McCord Hospital using TrackCare
softwareandcross-referenced theserecords with papercharts.AtSt.
Mary’s Hospital, we evaluated conventional paper medical records
and, due to a change in documentation procedures at St. Mary’s
Hospital, we did not include medical records prior to 2007. We
entered the following data into a Microsoft Access database: age at
ART initiation, gender, ART regimen, presence of tuberculosis
(TB) and non-TB opportunistic infections, chronic diarrhea (longer
than 14 days), and baseline laboratory results including: absolute
and CD4 percentage, hemoglobin and baseline weight-for-age Z-
scores (WAZ) (calculated for all children less than 10 years of age
using the WHO macro for STATA; https://www.who.int/
childgrowth/software). We recorded the presence of chronic
diarrhea, tuberculosis and opportunistic infections based on their
presence in the electronic medical record and following a review of
the hard copy paper records. We defined opportunistic infections
(OI) as the presence of: oral candidiasis, Kaposi’s sarcoma,
Pneumocystis jiroveci pneumonia, cryptococcosis, toxoplasmosis,
or cryptosporidiosis. We treated all OIs according to the South
African National Treatment Guidelines for Children [20]. If these
conditions were not documented in the electronic medical record or
paper charts, we reported them as absent.
Missing Data. In multivariate analysis, we only analyzed
subjects with complete data. No data was imputed for this analysis.
Definition of Poor CD4 Recovery. We defined poor CD4
recovery for children less than 5 years old on therapy for more
than 24 weeks as: less than five point increase CD4% or CD4%
remaining less than 15%. For children older than 5 years, poor
CD4 recovery was defined as: ,10% increase in absolute CD4, or
absolute CD4 remaining below 200 cells/mm
3. These definitions
were based on the WHO classification of immunological failure
for children [21] and adolescents [22] and other reports in the
literature [10].
Definition of Poor WAZ Response. We defined poor
weight gain based on weight-for-age Z-scores (WAZ). We,
therefore, limited the analysis to children less than 10 years old
because WHO weight standardizations only exist for this age
group. Poor WAZ response was defined as: any decrease from
pre-ART baseline WAZ after six months of ART, or less than
0.5 point increase in WAZ for children with baseline WAZ,20.5.
Statistical Analysis
We conducted statistical analyses using SAS statistical software
(Release 9.2, Carey, NC). Using logistic regression, we first
determined univariate associations between nine demographic and
clinical covariates, which, based upon clinical observations and
prior studies, were suspected to be potentially important correlates
of poor immunologic or clinical response. The covariates included:
age at initiation, sex, baseline absolute CD4, baseline CD4%,
baseline hemoglobin, baseline WAZ, presence of TB, presence of
OIs, and presence of chronic diarrhea. We stratified age into three
categories (,1 year old, 1–3 years old, and 3–10 years old) to
account for the age-related difference in ART treatment regimens.
For all analyses, we selected children ages 3–10 years as the
reference group. In our final model, we used multivariate logistic
regression controlling for age at initiation. The final model was
selected from the remaining eight covariate model using a
backward elimination procedure with p,0.05 considered signif-
icant to remain in the model.
We did not assess the association between type of ART regimen
(Protease Inhibitor verses Non-Nucleotide Reverse Transcriptase
Inhibitor) and CD4 or WAZ response in these analyses because
the ART regimen was selected based on age and, thus, these
variables were highly correlated (Pearson correlation coefficient
(PCC)=0.79). In addition, absolute CD4 and CD4% were highly
correlated (PCC=0.65); therefore we chose to include only
CD4% as a covariate. Chronic diarrhea and OIs; and chronic
diarrhea and WAZ were not highly correlated (PCC=0.13 and
20.16 respectively); therefore, they were included as separate
covariates in the final models.
Predictors of Pediatric CD4 and Weight Recovery
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A total of 1,030 children initiated ART therapy at McCord
Hospital and St. Mary’s Hospital between August 2003 and
December 2008. Of these, 647 were eligible for the study
(Figure 1). Of those who were ineligible: 127 patients were missing
baseline CD4 results; 69 children died, were lost to follow up or
transferred to another facility within the first six months of ART;
21 children transferred into care without documentation; 10
children did not have CD4 results within the first 12 months of
therapy; and 129 children were older than 10 years at ART
initiation. Clinical and demographic characteristics for this cohort
of children ,10 years old are located in Table 1. After six months
of ART, 587 had complete results. After 12 months of ART, 467
children had complete results. Due to the amount of missing and
unavailable data, we evaluated characteristics of those children
with and without available follow-up results (Table 1). At six
months, there was no statistically significant difference between
those children with available results and those with unavailable
results. At 12 months, those with available results had higher
baseline absolute CD4 and had a higher rate of tuberculosis at
ART initiation.
Overall response to ART is shown in Figure 2. Viral
suppression rates (to less than 400 copies/ml) were 84% after six
months of therapy and 88% after 12 months of therapy. CD4
recovery (as defined above) was achieved in 73% of children after
six months and 89% after 12 months. After six months of ART,
58% of children had improved WAZ (defined above), and 64% of
children achieved an improved WAZ after 12 months. Mortality
in this cohort was 8.8%. There was no difference in viral
suppression, immunologic response or weight response based on
location of care.
Predictors of CD4 Recovery
We performed univariate logistic regression (Table 2) and
multivariate logistic regression (Table 3) to identify predictors of
CD4 response to ART after six and 12 months of therapy. The
final multivariate logistic regression model for the six-month
analysis revealed that presence of chronic diarrhea (p=0.007),
lower baseline hemoglobin (p=0.037) and virologic failure
(p=0.046) were significantly associated with poor CD4 recovery.
In multivariate analysis, children with documented chronic
diarrhea at baseline were more likely to have poor CD4 recovery
(OR=2.05; 95% CI 1.22–3.46) independent of baseline nutri-
tional status. Children with lower baseline hemoglobin had
significantly worse CD4 recovery (OR=0.87 for each 1 g/dl
decrease in hemoglobin; 95% CI 0.75–0.99). Additionally,
children whose viral load remained .400 copies/ml at six months
were more likely to have poor CD4 recovery at six months
(OR=1.75; 95% CI: 1.01–3.03).
After 12 months on ART, multivariate logistic regression
revealed that higher baseline CD4%, presence of baseline chronic
diarrhea and virologic failure were significantly associated with
poor CD4 recovery (p=0.005; p=0.02; p,0.001, respectively)
Figure 1. Selection of Children for Analysis from a Cohort of HIV-infected ,10 Years Old Children Initiating ART, South Africa,
August 2003–December 2008.
doi:10.1371/journal.pone.0033611.g001
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baseline were more likely to have poor CD4 recovery at 12 months
(OR=2.58; 95% CI: 1.15–5.79). Virologic failure at 12 months
was the strongest predictor of CD4 response at 12 months.
Children who did not have suppressed viral loads after 12 months
of ART were more likely to have poor CD4 recovery (OR=4.01;
95% CI: 1.77–9.07).
Predictors of WAZ Improvement
Next, we performed univariate logistic regression (Table 4) and
multivariate logistic regression (Table 5) to evaluate weight gain
following ART initiation. The final multivariate logistic regression
model for the six-month analysis revealed that age at initiation
(p,0.001), baseline CD4% (p,0.001) and baseline WAZ
(p,0.001) were significantly associated with weight response.
Table 1. Baseline Clinical and Demographic Characteristics of a Cohort of HIV-infected ,10 Years Old Children Initiating ART, by
CD4 Availability at Six and 12 months, South Africa, August 2003–December 2008.
6 Months 12 Months
Covariate
Results Available
N=587
Results Not
Available N=87 P-value
Results Available
N=467
Results Not
Available N=207 P-value
Median Age at Initiation (years)[IQR] 4.0 [1.4–6.8] 4.0 [1.1–7.4] 0.94 4.1 [1.5–6.8] 3.6 [1.3–6.9] 0.62
Females 48% 44% 0.49 45% 53% 0.54
Baseline CD4 (Median) (cells/mL) [IQR] 364 [143–686] 364 [157–723] 0.90 358 [133–665] 380 [196–754] 0.09
Baseline CD4 Percent (Median) [IQR] 12 [6.6–16.3] 12 [6–19] 0.58 12 [6–15] 13 [8–19] 0.001
Baseline Hemoglobin (Median) (g/dl) [IQR] 9.8 [8.6–10.7] 10.0 [9.1–10.6] 0.31 9.9 [8.7–10.7] 9.6 [8.4–10.7] 0.23
NNRTI* 61.5% 62.1% 1 63.2% 58.0% 0.23
TB Co-infection{ 37.3% 28.7% 0.15 33.0% 43.5% 0.01
Chronic Diarrhea 14.1% 12.9% 0.87 14.6% 12.6% 0.55
Baseline Weight for Age Z-score (Median) [IQR] 21.2 [22.4–20.4] 21.3 [22.3–20.1] 0.72 21.3 [22.5–0.4] 21.1 [22.3–20.4] 0.84
Opportunistic Infection{ 23.8% 21.8% 0.79 24.6% 21.3% 0.38
*Children less than 3 years are started on a PI-based regimen while children over 3 years are started on an NNRTI-based regimen.
{Baseline tuberculosis co-infection.
{Opportunistic infection includes children with the presence of candidiasis, Kaposi’s sarcoma, Pneumocystis jiroveci pneumonia, cryptococcosis, toxoplasmosis, or
cryptosporidiosis.
doi:10.1371/journal.pone.0033611.t001
Figure 2. Percentage Response to ART at Six and 12 Months for a Cohort of HIV-infected ,10 Years Old Children Initiating ART,
South Africa, August 2003–December 2008.
doi:10.1371/journal.pone.0033611.g002
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likely to experience a poor weight response compared to children
aged 1–3 years at initiation (p=0.008; 95% CI: 0.31–0.84) and
those less than 1 year old (p,0.001; 95% CI 0.17–0.58). Children
with lower baseline WAZ had improved WAZ compared to
children with a higher baseline WAZ. There was a 44% increase
in adequate WAZ response for every one point lower baseline
WAZ (OR=1.44; 95% CI: 1.26–1.65). After 12 months on ART,
baseline WAZ was the only variable significantly associated with
adequate WAZ response (p,0.0001) controlling for age at
initiation.
Discussion
The increased availability and earlier initiation of ART in HIV-
infected children in sub-Saharan Africa has led to dramatic
improvement in the care for HIV-infected children. However, the
response to therapy is variable, and many children exhibit poor
immunologic response to therapy that may increase their risk of
morbidity and mortality despite ART. In this cohort of children
,10 years old at ART initiation, we observed that the presence of
chronic diarrhea at baseline and virologic failure predicted poorer
CD4 outcomes at six and 12 months post-ART initiation. These
data may be useful for identifying children at higher risk of poor
outcomes who would require closer clinical monitoring.
Our data indicate that the presence of chronic diarrhea at
baseline, independent of nutritional status, predicts poor CD4
recovery. Chronic diarrhea has been described as a risk factor for
early mortality in HIV-infected children [17] and adults [23,24]
but has not been previously associated with poor CD4 recovery.
Since children who died prior to six months of ART were
excluded from this analysis, the effect of chronic diarrhea on CD4
recovery in HIV-infected children initiating ART may be
understated. The mechanism by which baseline chronic diarrhea
leads to poor CD4 recovery in children remains unclear.
Malabsorption of ART could theoretically play a role in slower
CD4 recovery; however, the observed association was independent
of virologic response to therapy. Although children with chronic
Table 2. Univariate Predictors of Poor CD4 Response From a Cohort of HIV-infected ,10 Years Old Children Initiating ART in South
Africa, August 2003–December 2008.
6 Months N=587 12 Months N=467
Odds Ratio [95% CI] P-value Odds Ratio [95% CI] P-value
Age at Initiation* 0.005 0.26
Age ,1 year 2.1 [1.4–3.4] 0.001 1.54 [0.80–2.96] 0.19
Age 1–3 years 1.4 [0.9–2.2] 0.14 0.80 [0.29–1.65] 0.54
Females 0.93 [0.97–1.02] 0.68 1.15 [0.67–1.98] 0.61
Baseline CD4 % 1 [0.97–1.02] 0.98 1.07 [1.03–1.11] 0.0002
Baseline Hemoglobin 0.81 [0.71–0.92] 0.001 1.02 [0.89–1.19] 0.77
TB Co-infection 1.15 [0.79–1.68] 0.46 0.93 [0.52–1.67] 0.82
Chronic Diarrhea 1.85 [1.14–2.99] 0.01 1.78 [0.90–3.48] 0.09
Baseline WAZ 0.99 [0.89–1.10] 0.80 0.99 [0.84–1.19] 0.98
Opportunistic Infection{ 1.53 [1.02–2.31] 0.04 0.83 [0.43–1.59] 0.57
Viral Failure 2.08 [1.20–3.34] 0.003 2.03 [0.96–4.30] 0.06
*Age was treated as a categorical variable including age ,1 year, 1–3 years, 3–10 years, where children 3–10 were the reference group.
{Opportunistic infection includes children with the presence of candidiasis, Kaposi’s sarcoma, Pneumocystis jiroveci pneumonia, cryptococcosis, toxoplasmosis, or
cryptosporidiosis, while the reference group did not have any of these opportunistic infections.
doi:10.1371/journal.pone.0033611.t002
Table 3. Multivariate Predictors of Poor CD4 Response From a Cohort of HIV-infected ,10 Years Old Children Initiating ART in
South Africa, August 2003–December 2008.
6 Months{ N=587 12 Months{ N=476
Odds Ratio [95% CI] P-value Odds Ratio [95% CI] P-value
Age at Initiation* 0.13 0.99
Baseline Cd4% 1.07 [1.02–1.13] 0.005
Baseline Hemoglobin 0.87 [0.75–0.99] 0.037
Chronic Diarrhea 2.05 [1.22–3.46] 0.007 2.58 [1.15–5.79] 0.02
Viral Failure 1.75 [1.01–3.03] 0.046 4.01 [1.77–9.07] 0.0009
*Age was treated as a categorical variable including age ,1 year, 1–3 years, 3–10 years, where children 3–10 were the reference group.
{In the 6 month multivariate logistic regression model age at initiation was forced in and baseline hemoglobin, chronic diarrhea and viral failure were selected by
backward elimination procedure with p,0.05 as criteria for inclusion in the model.
{In the 12 month multivariate logistic regression model age at initiation was forced in and baseline CD4%, chronic diarrhea and viral failure were selected by backward
elimination procedure with p,0.05 as criteria for inclusion in the model.
doi:10.1371/journal.pone.0033611.t003
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permeability, local expression of inflammatory cytokines, and
greater T-cell activation [25,26,27], it is not known whether or by
what mechanism this localized GI inflammation contributes to
delayed systemic CD4 recovery in HIV-infected children.
Whether the presence of chronic diarrhea in HIV-infected
children reflects the gut enteropathy that immediately follows
HIV-1 infection warrants further investigation [28,29].
Adults with immunologic failure have been found to have
increased markers of microbial translocation and immune
activation; [12]. This previously has not been linked to baseline
presence of chronic diarrhea. However, bacterial products have
been shown to induce a permanent inflammatory state in the GI
tract, which potentiates HIV replication and the associated T-cell
depletion in the gut-associated lymphoid tissue (GALT) [30]. In
addition, the rapid depletion of CD4 T cells from GALT during
acute infection and the delayed recovery of GALT CD4 T cells
after initiation of ART during chronic infection [31], could
influence the interaction between chronic diarrhea and poor
peripheral recovery of CD4 T cells. The poor CD4 response to
ART among HIV-infected children with chronic diarrhea
warrants further mechanistic investigation that could lead to
potential therapeutic interventions.
Our data are in agreement with other pediatric studies
suggesting that viral suppression is highly predictive of CD4
recovery [9,11]. Our data suggest that viral suppression is the
strongest predictor of CD4 recovery by 12 months of therapy. This
finding emphasizes the overall importance of virologic monitoring.
Moreover, it suggests that significant cost savings may be achieved
in resource-limited settings by limiting CD4 monitoring to
children with documented virologic failure. In this cohort, if
CD4 monitoring was performed after six months of therapy only
for those with virologic failure, it would have led to a cost savings
of 110,000 Rand (approximately $15,715 US Dollars) in one year.
Fewer than 10% of children in our cohort who achieved virologic
suppression at 12 months of ART had a poor immunologic
response. Conversely, only 8% of children with virologic failure at
12 months had an adequate CD4 response.
Children less than three years old at initiation, those with lower
baseline CD4%, and those with lower baseline WAZ more
Table 4. Univariate Predictors of Poor WAZ Response From a Cohort of HIV-infected ,10 Years Old Children Initiating ART in
South Africa, August 2003–December 2008.
6 Months N=587 12 Months N=476
Odds Ratio [95% CI] P-value Odds Ratio [95% CI] P-value
Age at initiation* 0.005 0.04
Age ,1 year 0.47 [0.39–0.77] 0.003 0.60 [0.35–1.02] 0.058
Age 1–3 years 0.64 [0.42–0.99] 0.047 0.58 [0.35–0.97] 0.037
Females 1.21 [0.85–1.72] 0.29 1.23 [0.82–1.85] 0.31
Baseline CD4 % 1.05 [1.02–1.07] 0.0005 1.01 [0.98–1.03] 0.76
Baseline Hemoglobin 1.16 [1.03–1.31] 0.016 1.21 [1.06–1.39] 0.006
TB Co-infection 0.70 [0.49–1.01] 0.056 0.94 [0.61–1.44] 0.77
Chronic Diarrhea 0.54 [0.33–0.91] 0.021 0.69 [0.39–1.22] 0.20
Baseline WAZ 1.47 [1.30–1.67] ,0.0001 1.53 [1.33–1.77] ,0.0001
Opportunistic Infection 0.67 [0.44–1.02] 0.06 0.54 [0.33–0.89] 0.015
Viral Failure 0.54 [0.32–0.92] 0.02 0.67 [0.36–1.25] 0.21
*Age was treated as a categorical variable including age ,1 year, 1–3 years, 3–10 years, where children age 3–10 years were used as the reference group.
doi:10.1371/journal.pone.0033611.t004
Table 5. Multivariate Predictors of Poor WAZ Response From a Cohort of HIV-infected ,10 Years Old Children Initiating ART in
South Africa, August 2003–December 2008.
6 Months{ N=587 12 Months{ N=476
Odds Ratio [95% CI] P-value Odds Ratio [95% CI] P-value
Age at Initiation* 0.0003 0.18
Age ,1 0.32 [0.17–0.58] 0.0002 0.72 [0.39–1.33] 0.29
Age 1–3 0.51 [0.31–0.84] 0.008 0.59 [0.33–1.07] 0.08
Baseline CD4% 1.07 [1.03–1.10] ,0.0001
Baseline WAZ 1.44 [1.26–1.65] ,0.0001 1.60 [1.37–1.88] ,0.0001
*Age was treated as a categorical variable including age ,1 year, 1–3 years, 3–10 years with children 3–10 years serving as the reference group.
{In the 6 month multivariate logistic regression model age at initiation was forced in and baseline CD4% and baseline WAZ were selected by backward elimination
procedure with p,0.05 as criteria for inclusion in the model.
{In the 12 month multivariate logistic regression model age at initiation was forced in and baseline WAZ, was selected by backward elimination procedure with p,0.05
as criteria for inclusion in the model.
doi:10.1371/journal.pone.0033611.t005
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After 12 months of ART, we observed that children with lower
baseline WAZ had better improvement in WAZ. These findings
suggest a more robust response to weight gain in malnourished
children initiating ART compared to non-malnourished children,
as seen in other African pediatric HIV cohorts [1,32]. In addition,
we observed a greater weight response to ART in children with
greater baseline immunosuppression. This effect is consistent with
findings from other pediatric cohorts [2,33]. In our cohort, viral
suppression did not predict weight gain. However, a cohort from
Spain found children with virologic failure had worse clinical
outcomes and poor weight gain compared to those with viral
suppression [5]. However, in the Spanish cohort, the children had
a higher baseline WAZ (20.45) compared to our cohort (21.3),
allowing for less change in WAZ from baseline to within normal
limits.
There are several important limitations to this study. Because
this was a retrospective study, observational data, including
tuberculosis infections, opportunistic infections and chronic
diarrhea, may have been unrecorded, potentially biasing our
analyses toward the null hypothesis. Many subjects had missing
data and were excluded from the analysis. While no difference was
seen in clinical or demographic characteristics between those with
missing information and those analyzed at six months, those with
unavailable results at 12 months had a slightly higher CD4
percentage and a higher rate of tuberculosis, which could limit the
generalizability of the 12-month data. We based our definitions of
poor CD4 recovery on clinical and WHO-based guidelines for
immunological failure [21,22]. Likewise, we based our definition
of poor weight gain on prior reports from the literature [10].
However, there is no clear consensus definition for these outcomes
in children. Finally, we were unable to record several potentially
significant confounders for the WAZ response outcome, including
family income and food insecurity. Analysis of McCord’s urban
population (who pay user fees) and St. Mary’s rural population
(who do not pay user fees) showed no difference in viral
suppression rates, CD4 response or WAZ response.
Because South African ART guidelines mandate NNRTI-based
ART for children initiating therapy after 3 years of age and PI-
based therapy for younger children, age and ART regimen are
inextricably linked in our cohort. Therefore, any observed age-
related difference between children less than 3 years old and those
older than 3 years old could be confounded by a differential
response to PI- and NNRTI-based treatment regimens. PI-based
regimens produce a more rapid increase in CD4 recovery
compared to NNRTI-based regimens in adults after 12 weeks of
ART [34]. However, there was no difference in CD4 response
based on age in our cohort of children ,10 years old.
It seems prudent that clinician should closely monitor children
less than 1 year old at ART initiation, those with chronic diarrhea
at baseline, low baseline WAZ and virologic failure due to an
increased risk for poor immune response and/or poor weight gain.
Increased access to treatment and early ART initiation will
hopefully decrease the amount of chronic diarrhea seen in this
pediatric population. Understanding this mechanism of poor CD4
recovery and the interaction between chronic diarrhea, immune
activation, microbial translocation and GALT CD4 depletion may
lead to adjunctive therapies in the treatment of pediatric HIV
infection.
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